



Training modules for GSK's hepatitis A and B vaccines now available on Health.GSK.ca*

We are pleased to offer a series of 4 training modules focusing on GSK's hepatitis A and B vaccines. These modules aim to provide guidance on how you can help patients travelling to endemic countries.

- Module 1: Hepatitis B
- Module 2: Hepatitis A
- Module 3: GSK's Hepatitis A&B vaccines
- Module 4: Implementation tips

You can complete these modules at any time from the comfort of your home or office.

START NOW

TWINRIX® combined hepatitis A (inactivated) and B (recombinant) vaccine

Indications and Clinical Use:

TWINRIX® is indicated for:

- active immunization against hepatitis A and hepatitis B virus infection in adults, adolescents, children and infants.

The vaccine will not protect against infection caused by other agents such as hepatitis C, hepatitis E and other pathogens known to infect the liver. It can be expected that hepatitis D will also be prevented by immunization with TWINRIX® as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.

HAVRIX® hepatitis A vaccine (inactivated)

Indications and Clinical Use:

HAVRIX® is indicated for:

- active immunization against hepatitis A virus (HAV) infection in subjects at risk of exposure to HAV.

The vaccine will not prevent hepatitis infection caused by other agents such as hepatitis B virus, hepatitis C virus, hepatitis E virus or other pathogens known to infect the liver.

ENGERIX®-B hepatitis B vaccine (recombinant)

Indications and Clinical Use:

ENGERIX®-B is indicated for:

- active immunization against hepatitis B virus infection.

The vaccine will not protect against infection caused by hepatitis A and non-A non-B hepatitis viruses. As hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection or carrier state, it can be expected that hepatitis D will also be prevented by vaccination with ENGERIX®-B.

For more information:

Please consult the TWINRIX® Product Monograph at gsk.ca/twinrix/pm, the HAVRIX® Product Monograph at gsk.ca/havrix/pm, and the ENGERIX®-B Product Monograph at gsk.ca/engerix/pm for important information relating to contraindications, warnings and precautions, adverse reactions, drug interactions, dosing and administration, and conditions of clinical use.

To report an adverse event, or to request a Product Monograph, please call us at 1-800-387-7374.

References: 1. Product Monograph for TWINRIX®, GlaxoSmithKline Inc., August 11, 2016. 2. Product Monograph for HAVRIX®, GlaxoSmithKline Inc., March 21, 2016. 3. Product Monograph for ENGERIX®-B. GlaxoSmithKline Inc., October 19, 2015.

*Health.GSK is a gated site restricted to licensed healthcare professionals.

Funded and organized by GSK.

This session is for licensed healthcare professionals only.

This is not a Continuing Medical Education event and has not been accredited.

TWINRIX is a registered trademark of GlaxoSmithKline Biologicals SA, used under license by GSK, Inc.

© 2016 GSK, Inc. All rights reserved.